Active Healthcare ETF TMED Sending Buy Signal

Core Insights - Active ETFs are gaining significance among investors, with flows expected to reach another record due to increasing launches [1] - The T. Rowe Price Health Care ETF (TMED) has shown strong performance, returning 11.8% over the last three months and 10% over the last month, outperforming its category averages [1] - TMED's active management and fundamental research focus are key drivers of its solid returns, investing in a diverse range of healthcare stocks globally [1] Performance Metrics - TMED charges a fee of 44 basis points and has outperformed the ETF Database Category average of 8% and 6.3% over three and one-month periods, respectively [1] - The FactSet Segment averages were 7.6% and 5.3% for the same periods, indicating TMED's superior performance [1] - As of October 6, TMED's price was $27.97, above its 50-day simple moving average of $25.37, signaling a buy opportunity [1] Investment Strategy - TMED employs a bottom-up investment approach, holding a portfolio of 100–150 stocks across biotechnology, pharmaceuticals, products and device providers, and healthcare service companies [1] - The ETF's active strategy may benefit from falling interest rates and ongoing AI innovations, which could enhance productivity and innovation in the healthcare sector [1]